Oncolytics Biotech Inc. (ONCY) Earnings
Oncolytics Biotech Inc. is expected to report next earnings on August 14, 2026 (in NaN days), with a consensus EPS estimate of $-0.07. ONCY has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -5.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.05 | $-0.08 | -60.0% | — | — |
| Mar 30, 2026 | $-0.06 | $-0.08 | -33.3% | — | — |
| Nov 12, 2025 | $-0.12 | $-0.10 | +16.7% | — | — |
| Aug 8, 2025 | $-0.11 | $-0.05 | +54.5% | — | — |
| May 14, 2025 | $-0.09 | $-0.06 | +33.3% | — | — |
| Mar 7, 2025 | $-0.08 | $-0.07 | +12.5% | — | — |
| Aug 1, 2024 | $-0.08 | $-0.07 | +12.5% | — | — |
| May 9, 2024 | $-0.09 | $-0.07 | +22.2% | — | — |
| Mar 7, 2024 | $-0.11 | $-0.04 | +63.6% | — | — |
| Nov 3, 2023 | $-0.07 | $-0.10 | -42.9% | — | — |
| Aug 14, 2023 | $-0.09 | $-0.09 | +0.0% | — | — |
| May 5, 2023 | $-0.07 | $-0.07 | +0.0% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2025 · May 14, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- CEO search is active with several excellent candidates being met; aiming to find a leader for pelareorep focused on clinical trial execution. - Clinical data of pelareorep exceeds expectations, with potential in pancreatic, breast, and anal carcinomas which have high unmet medical needs. - GOBLET Cohort 4 in anal carcinoma showed 33% objective response rate, with expansion to Stage 2; Cohort 5 in pancreatic cancer is enrolling and has completed safety run-in phase. - Breast cancer results from IND-213 and BRACELET-1 studies show pela-based combination therapy outperforms standard of care; multiple options for continued development in breast cancer. - Business development activities ongoing, with interactions at JPMorgan, ASCO, and BIO; pelareorep has a remarkable safety profile with over 1,100 patients treated. - $20 million share purchase agreement with Alumni Capital provides access to capital to extend financial runway.
Guidance
- Cash and cash equivalents of $15.3 million provide runway through key milestones and into the third quarter of 2025. - $20 million share purchase agreement with Alumni Capital helps extend financial runway. - Upcoming poster presentation on pelareorep's mechanism at ASCO.
Segment performance
As of March 31, 2025, Oncolytics Biotech had cash and cash equivalents of $15.3 million. Net cash used in operating activities for the quarter was $6.5 million, down from $7.5 million in the same period last year. General and administrative expenses were $3 million for the first quarter, consistent with the prior year. Research and development expenses totaled $4.1 million, down from $5.7 million in Q1 of 2024. The net loss for the quarter was $6.7 million or $0.08 per basic and diluted share compared to a net loss of $6.9 million, $0.09 per share in Q1 of 2024.
Risks & headwinds
- Factors including results of current pending clinical trials, risks associated with intellectual property, financial projections, actions by regulatory agencies, and other factors detailed in the Company's filings with SEDAR and the SEC may cause actual results to differ from forward-looking statements.
Analyst Q&A
Q: Congrats on all the progress. Regarding the anticipated start of the registrational trial in HR-positive/HER2-negative metastatic breast cancer, what can you share about the potential trial design for the study. Will PFS be a primary endpoint? And how are you incorporating feedback from regulatory agencies? And then separately, have there been any recent interactions with the FDA or other regulatory bodies regarding the pancreatic cancer program? And what feedback, if any of you received concerning potential registrational pathways.
A: Dr. Tom Heineman responded that they discussed the study with the FDA at a Type C meeting in the second or third quarter of last year, anticipate progression-free survival as the primary endpoint in the next breast cancer study. On pancreatic cancer, the FDA is aware of the program including fast-track approval, working with GCAR on a protocol, but no recent FDA discussions.
Q: On the business development activities. I'm wondering if there are specific areas like regional rights or co-development opportunities or other areas that are being prioritized? And then just given pelareorep's mechanism of action, are there plans to explore additional combination approaches maybe with immune checkpoint inhibitors or in other tumor types?
A: Christophe Degois said they are looking at different partnerships for breast and pancreatic as top priorities, considering global or regional rights. Dr. Tom Heineman added they are exploring combination with checkpoint inhibitors, showing synergy in pancreatic and breast cancer, and will leverage on an indication-by-indication basis.